Adipokines--targeting a root cause of cardiometabolic risk.
Obesity often co-presents with other cardiometabolic risk factors such as dyslipidaemia, insulin resistance and hypertension. Less well appreciated is that dysregulation of adipokine production by excess adipose tissue also promotes a state of low-level systemic chronic inflammation and a prothrombotic state, implicated in the development of both atherosclerosis and subsequently cardiovascular events. Lifestyle modification and pharmacological therapy can reduce cardiometabolic risk, a benefit that may be partly due to their effects on adipokine levels.
Bakhai
A
A
Thames House, Barnet General Hospital, Barnet & Chase Farm NHS Trust, Wellhouse Lane, Barnet EN5 3DJ, England, UK. Ameet.Bakhai@bcf.nhs.uk
D054392:Adipokines / Q000378:metabolism*; D000273:Adipose Tissue / Q000378:metabolism; D050197:Atherosclerosis / Q000209:etiology*; D053480:Cholesterol Ester Transfer Proteins / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D003925:Diabetic Angiopathies / Q000209:etiology; D050171:Dyslipidemias / Q000209:etiology* / Q000503:physiopathology; D005234:Fatty Liver / Q000209:etiology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008019:Life Style; D009765:Obesity / Q000150:complications*; D012307:Risk Factors; D015431:Weight Loss / Q000502:physiology
D054392:Adipokines; D053480:Cholesterol Ester Transfer Proteins